Literature DB >> 18283609

Delivering silence: advancements in developing siRNA therapeutics.

Tatiana I Novobrantseva1, Akin Akinc, Anna Borodovsky, Antonin de Fougerolles.   

Abstract

The number of small interfering RNA (siRNA)-based therapeutics that are in or nearing human clinical trials is rapidly expanding. This review summarizes recent in vivo data obtained from studies on siRNA therapeutics and gives an overview of the key in vivo delivery technologies in use today. A section is also devoted to currently ongoing clinical trials employing siRNA drugs.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18283609

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN： 1367-6733


  15 in total

Review 1.  Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.

Authors:  Yunching Chen; Leaf Huang
Journal:  Expert Opin Drug Deliv       Date:  2008-12       Impact factor: 6.648

2.  In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR).

Authors:  Yosef Landesman; Nenad Svrzikapa; Armand Cognetta; Xuemei Zhang; Brian R Bettencourt; Satya Kuchimanchi; Keri Dufault; Sarfraz Shaikh; Maple Gioia; Akin Akinc; Renta Hutabarat; Rachel Meyers
Journal:  Silence       Date:  2010-08-23

3.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

Authors:  Sancy A Leachman; Robyn P Hickerson; Mary E Schwartz; Emily E Bullough; Stephen L Hutcherson; Kenneth M Boucher; C David Hansen; Mark J Eliason; G Susan Srivatsa; Douglas J Kornbrust; Frances Jd Smith; Wh Irwin McLean; Leonard M Milstone; Roger L Kaspar
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

4.  Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model.

Authors:  Chunting Ye; Jang-Gi Choi; Sojan Abraham; Haoquan Wu; Dolores Diaz; Daniel Terreros; Premlata Shankar; N Manjunath
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-03       Impact factor: 11.205

5.  Stability study of unmodified siRNA and relevance to clinical use.

Authors:  Robyn P Hickerson; Alexander V Vlassov; Qian Wang; Devin Leake; Heini Ilves; Emilio Gonzalez-Gonzalez; Christopher H Contag; Brian H Johnston; Roger L Kaspar
Journal:  Oligonucleotides       Date:  2008-12

Review 6.  Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies.

Authors:  Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-07       Impact factor: 11.382

7.  A status report on RNAi therapeutics.

Authors:  Akshay K Vaishnaw; Jared Gollob; Christina Gamba-Vitalo; Renta Hutabarat; Dinah Sah; Rachel Meyers; Tony de Fougerolles; John Maraganore
Journal:  Silence       Date:  2010-07-08

8.  Sequence determinants of innate immune activation by short interfering RNAs.

Authors:  Amber Goodchild; Nicole Nopper; Andrew King; Tram Doan; Marcel Tanudji; Greg M Arndt; Michael Poidinger; Laurent P Rivory; Toby Passioura
Journal:  BMC Immunol       Date:  2009-07-24       Impact factor: 3.615

9.  Specific Jak3 Downregulation in Lymphocytes Impairs γc Cytokine Signal Transduction and Alleviates Antigen-driven Inflammation In Vivo.

Authors:  Alicia G Gómez-Valadés; María Llamas; Sílvia Blanch; José C Perales; Juan Román; Lluís Gómez-Casajús; Cristina Mascaró
Journal:  Mol Ther Nucleic Acids       Date:  2012-09-04       Impact factor: 10.183

10.  RNAi Therapeutic Platforms for Lung Diseases.

Authors:  Yu Fujita; Fumitaka Takeshita; Kazuyoshi Kuwano; Takahiro Ochiya
Journal:  Pharmaceuticals (Basel)       Date:  2013-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.